IL6R

Across TCGA pan-cancer cohorts, IL6R mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IL6R data layer compared with 20 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IL6R mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IL6R expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where IL6R mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.546	0.932	.013	36	view →
CCRCC	DFS	Median	III,IV	0.185	0.948	.008	22	view →
LUAD	OS	Tertile	All	1.000	0.606	.022	4	view →
GBM	DFS	Quartile	All	0.159	0.401	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IL6R–PDAC (OS)

Open the PDAC breakdown →